Sana Biotechnology (SANA) Corporate presentation summary

Addressing unmet needs in type 1 diabetes

• Approximately 10 million people worldwide live with type 1 diabetes, facing significant disease burden and limited by current insulin-based therapies.

• Even with advanced care, life expectancy remains a decade shorter, and patients seek alternatives to insulin replacement.

Hypoimmune technology and clinical validation

• Hypoimmune gene edits enable islet cell transplants without immunosuppression, overcoming a major barrier in cell therapy.

• Clinical trial in a T1D patient showed allogeneic HIP islet cells survived and functioned for at least one year without immunosuppression or adverse events.

• No immune response detected against HIP-modified cells at 12 months, with sustained C-peptide production and graft visibility on imaging.

SC451 program and development progress

• SC451 aims to deliver stem cell-derived, hypoimmune islet cells as a single therapy for broad T1D populations, with IND filing and Phase 1 trial targeted for 2026.

• Manufacturing scale-up, regulatory dialogues, and clinical planning advanced in 2025, with clear Phase 1 success criteria: safety, cell survival, and insulin production.

• Next steps include completing GLP toxicology, tech transfer, and initiating clinical trials.